ProQR +3% on receiving Fast Track designation for QR-421a for usher syndrome type 2

|About: ProQR Therapeutics (PRQR)|By:, SA News Editor

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received Fast Track designation from the FDA for QR-421a, an investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa.

Fast Track provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

Shares are up 3% premarket.

Subscribe for full text news in your inbox